ERYTECH-PHARMA
Regulatory News:
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP & OTC US: EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces its financial calendar for 2015.
| February 10, 2015: | Publication of full year 2014 revenues (after market) | ||
| March 30, 2015: | Publication of 2014 annual results (after market) | ||
| May 5, 2015: | Publication of Q1 2015 revenues (after market) | ||
| June 23, 2015: | Annual shareholders’ meeting | ||
| July 8, 2015: | Publication of Q2 2015 revenues (after market) | ||
| September 28, 2015: | Publication of H1 2015 results (after market) | ||
| November 3, 2015: | Publication of Q3 2015 revenues (after market) |
Beyond these periodicals, investors are invited to consult the website of the company (www.erytech.com ) where information is regularly updated. All corporate and financial information on the company is available on the company’s website, in the Investors’ section.
About ERYTECH: www.erytech.com
Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors.
By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed ERY-ASP/GRASPA® , an original treatment that targets cancer cells through “tumor starvation” while significantly reducing the side effects for patients. ERY-ASP/GRASPA® has recently announced positive Phase III data in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb clinical trial in Acute Myeloid Leukemia (AML) in Europe. The product is also in Phase I/II clinical development in ALL in the USA.
Every year about 50,000 patients are diagnosed with Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML), the two forms of acute leukemia. Today, for about 80% of these patients, mainly adults and relapsing patients, current forms of asparaginase cannot be used due to their toxicity. With a presumed improved safety profile, ERY-ASP/GRASPA® is being developed to allow all leukemia patients to be treated, even the most fragile ones, representing a market opportunity of more than EUR 1 billion.
The company is also developing other indications in solid tumors and certain orphan indications outside oncology. A Phase II study in pancreas cancer is ongoing and the company is exploring other solid tumor indications for ERY-ASP.
ERYTECH has obtained orphan drug designations for ERY-ASP/GRASPA® in ALL, AML and pancreas cancer, both in Europe and the USA, and has its own GMP-approved and operational manufacturing site in Lyon (France), and a site for clinical production in Philadelphia (USA).
The company has concluded licensing and distribution partnership agreements for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL with TEVA in Israel.
ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid&Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the US under an ADR level 1 program (OTC, ticker EYRYY).
Contact:
ERYTECH
Gil Beyen
Chairman and CEO
Tel:
+33 4 78 74 44 38
investors@erytech.com
or
NewCap
Julien
Perez / Emmanuel Huynh
Investor relations
Nicolas
Merigeau
Press relations
Tel: +33 1 44 71 98 52
erytech@newcap.fr
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 13:00:00 CEST | Press release
FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letterIf approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74
Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 13:00:00 CEST | Press release
Experts from Qualcomm, Viant Medical, and Thermo Fisher Scientific join Kinaxis and economic futurist Andrew Busch to share insights on navigating tariff volatility As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s comin
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 12:00:00 CEST | Press release
Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and future regulatory filingsPhase 1 study of BCL2 inhibitor sonrotoclax plus BRUKINSA® elicited deep responses – 96% ORR in R/R CLL and 79% ORR in R/R MCL patients – with no new safety signals in the latest resultsBTK degrader BGB-16673 shows strong early results in hard-to-treat populations BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce
Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 10:17:00 CEST | Press release
Fortune ranking aligns with Infobip’s innovative efforts in the IT industry and digital infrastructure Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involv
Craig Cook appointed Chief Business Officer and Co-founder at ABILITY Neurotech, the Wyss Geneva’s flagship spin-off12.6.2025 09:00:00 CEST | Press release
The Wyss Center for Bio and Neuroengineering proudly announces the appointment of Craig Cook, former Head of Business Development & Licensing at the Center, as Chief Business Officer and Co-founder of ABILITY Neurotech SA, a pioneering spin-off company translating breakthrough brain-computer interface (BCI) technology into clinical impact. During his tenure at the Wyss Center, Craig Cook played a transformative role in establishing a strong business development framework and positioning the organization as a venture builder in neurotechnology. Under his leadership, six breakthrough technologies were successfully spun out into operational startup companies: Clee Medical SA, Brainscape Medical SA, Dataflight Ltd, BrainQuant SA, Aleos Bio SA, and ABILITY Neurotech SA. In parallel, Craig led the onboarding of aligned startups such as Dandelion Science Corp. and dEEGtal Insights SA, strengthening our AI and neurotech ecosystem. He also contributed to Series A investments in two Wyss-affilia
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum